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Abstract
External signals that are mediated by specific receptors determine stem cell fate. The thrombin receptor PAR1 plays an
important role in haemostasis, thrombosis and vascular biology, but also in tumor biology and angiogenesis. Its expression
and function in hematopoietic stem cells is largely unknown. Here, we analyzed expression and function of PAR1 in primary
hematopoietic cells and their leukemic counterparts. AML patients’ blast cells expressed much lower levels of PAR1 mRNA
and protein than CD34+ progenitor cells. Constitutive Par1-deficiency in adult mice did not affect engraftment or stem cell
potential of hematopoietic cells. To model an AML with Par1-deficiency, we retrovirally introduced the oncogene MLL-AF9
in wild type and Par12/2 hematopoietic progenitor cells. Par1-deficiency did not alter initial leukemia development.
However, the loss of Par1 enhanced leukemic stem cell function in vitro and in vivo. Re-expression of PAR1 in Par12/2
leukemic stem cells delayed leukemogenesis in vivo. These data indicate that Par1 contributes to leukemic stem cell
maintenance.
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Introduction
The four Proteinase-Activated Receptors (PAR1 to PAR4)
belong to a superfamily of seven transmembrane, G-protein
coupled cell-surface receptors [1]. PARs receive various extracel-
lular signals and mediate them to intracellular responses and play
a prominent role in a variety of physiological processes [2,3].
Activation of PARs occurs usually via proteolytic cleavage of their
N-terminal exodomain through extracellular proteases like
thrombin. Cleavage creates a new N-terminus that serves as
tethered ligand and allows the activation of intracellular signal
cascades [4,5].
PAR1 as the prototype of this group is a high-affinity thrombin
receptor and it is therefore critical e.g. in thrombosis [3,6],
inflammation [7,8,9] and angiogenesis [10]. PAR1 can also be
activated by MMP-1, a matrix metalloprotease [2,11]. Absence of
Par1 is partially incompatible with embryonic development, since
at least half of Par1-deficient mice die around embryonic day E9.5
due to severe bleeding that could be rescued by the introduction of
Par1 expression in embryonic endothelial cells [10]. The surviving
mice do not exhibit obvious abnormalities [12,13]. Yue et al.
recently demonstrated that Par1 plays a role in the in vitro
differentiation of mouse embryonic stem cells into hematopoietic
progenitors and in endothelial-to-hematopoietic transition in
zebrafish [14]. However, the function of Par1 in adult hemato-
poiesis has not yet been addressed.
High PAR1 expression was found in tumors including
malignant melanoma [15] and breast cancer [16,17] and
correlated with invasiveness and motility of numerous cancer cell
lines [18,19,20,21], indicating that PAR1 might act as an
oncogene. Since the function of PAR1 in leukemia is yet unknown,
we here present the first report about PAR1 in adult hematopoiesis
and leukemogenesis. In particular, we identify PAR1 as a novel
regulator of leukemic stem cells in AML in an in vivo mouse model.
Materials and Methods
Patient samples and ethics statement
The study was reviewed and approved by the ethics committee
of the medical association and the medical faculty of the University
of Muenster (2007-524-f-S and 2007-390-f-S) before the study
began. AML samples were obtained from bone marrow of patients
with acute myeloid leukemia at the time of initial diagnosis. The
median blast count was 80%. For microarray analysis and RT-
PCR, CD34+ cells were obtained from the peripheral blood of
healthy donors who were stimulated with G-CSF using standard
protocols. Informed written consent was obtained from all
patients.
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Microarray analysis and data from the Leukemia Gene
Atlas
Published microarray data from human bone marrow and
blood cells were analyzed using the Leukemia Gene Atlas at
http://www.leukemia-gene-atlas.org (accessed 2014 Mar 25)
[22,23]. The analyzed cells were obtained from human umbilical
cord blood or from peripheral blood samples [23].
For comparison of control and AML patient samples, the
mRNA of 5 healthy CD34+ progenitor specimens and 67 AML
patient samples was hybridized on Whole Genome Microarrays.
Microarray data and the patient cohort were analyzed previously
[24]. Informed consent was obtained from all patients and donors.
RNA isolation and real-time quantitative RT-PCR
RNA isolation from patient samples and murine cells was
performed using RNeasy Micro Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s protocol.
Reverse transcription and real-time quantitative RT-PCR were
performed as described [25]. The probes were labeled at the 5’
end with the fluorescent dye FAM (PAR1) or VIC (GAPDH) and
at the 3’ end with the quencher TAMRA. Primer/Probe sets were
obtained from Life Technologies (Darmstadt, Germany;
‘‘Mm00438851_m1 F2r’’ for murine and ‘‘Hs00169258_m1
F2R’’ for human samples).
Flow cytometry, mice, colony assays, limiting dilution
transplantation, and competitive transplantations
FACS analyses of blood were performed as described [26]. HSC
FACS and sorting for HSC subpopulations was performed as
described [27].
Par1-Knockout (2/2) mice were obtained from Jackson
laboratory (Stock Number: 002862) [12] and genotyped as
published. Par12/2 mice survived with a lower frequency than
expectable according to Mendelian ratio, since we obtained only
32 Par12/2 mice out of 269 pubs (12% instead of expected 25%)
from matings of heterozygous parents.
All animal experiments in this study were carried out in strict
accordance with the recommendations of the Institutional Animal
Care and Use Committee ‘‘Landesamt fuer Natur, Umwelt und
Verbraucherschutz NRW’’. This study was performed with
permission of the Institutional Animal Care and Use Committee
and of the local veterinary administration of Muenster (Permit
Numbers: G15/2005, 8.87-51.04.20.09.322, and 8.87-
51.04.2011.A005).
For colony formation assays, bone marrow cells from three age-
matched Par1-wild type and – knockout mice were flushed from
femur and tibia of both hind legs using PBS/2% FCS and the red
cells were lysed by AKC shock as described [26]. 10,000 cells from
the total unsorted bone marrow or from c-kit+ bone marrow cells
and sorted by FACS as described above were seeded in M3434
methylcellulose (StemCell Technologies, Inc.) and counted after
7–8 days. Replating was performed by resolving the colonies in
PBS, seeding again 10,000 cells per ml methylcellulose and
counting as above.
For limiting dilution analysis, limiting amounts of donor cells
(100, 1000 or 10000 total bone marrow cells) from 3 pairs of
Par1+/+ (total of n= 44) vs. Par12/2 mice (total of n= 45) were
transplanted into irradiated (9 Gy) B6.SJL recipients along with
16105 wild type B6.SJL cells. Analysis of engraftment of
competitive repopulating units (CRU) was determined by FACS
analysis as the percentage of CD45.2 donor cells in the peripheral
blood 4 and 16 weeks after transplantation. Mice were scored
positive for CRU engraftment when the percentage of CD45.2
peripheral blood cells exceeded 0.1% and the percentage of
CD45.2+/CD11b+, CD45.2+/B220+, and CD45.2+/CD3+ cells
exceeded 0.02%. CRU frequencies in the blood were calculated
by applying Poisson statistics to the proportion of positive
recipients at different dilutions using Limiting Dilution Analyses
software L-Calc (StemCell Technologies Inc.).
Overexpression of PAR1 in murine cells
Human PAR1 cDNA was cloned into pEntry vector for
gateway system (Invitrogen) and then switched from pEntry vector
into the retroviral pMY-RFB destination vector, that contains a
green fluorescence (GFP) expressed from an internal ribosomal
entry site (IRES), by recombination reaction with LR-Clonase
(Invitrogen).
Retroviral supernatants were collected as described [26]. For
transduction, viruses were bound to retronectin-coated plates by
centrifugation as described [28]. Lineage-depleted bone marrow
cells were stimulated overnight, transduced by growth on the
virus-coated plates for 24 h and sorted by FACS for EGFP-
positivity. For colony assays, 1000 EGFP-positive cells per ml
methylcellulose M3434 (Stem Cell Technologies) were plated. The
total number of GFP-positive colonies was determined on day 10
after plating.
A total of 50,000 GFP-positive freshly transduced and FACS
sorted cells were injected with 50,000 wild type bone marrow cells
into the lateral tail vein of lethally irradiated (8.5 Gy) C57Bl/6N
mice. Fraction of GFP-positive cells was determined by FACS in
blood samples at the indicated time points after transplantation.
Tissue array construction and immunohistochemistry
analyses
Tissue array construction was performed of formalin-fixed and
paraffin embedded trephine bone marrow biopsies of 152 patients
diagnosed with primary, untreated AML and 7 samples of CD34+
cells was performed as described [29]. Informed consent was
obtained from all patients and donors. For PAR1 detection,
sections were incubated with the primary antibody (Thrombin R
antibody (H-111), sc-5605, Santa Cruz Biotechnology Inc., Dallas,
Texas, USA; dilution 1:100). PAR1 expression was regarded as
negative or positive.
Retroviral transduction and transplantations
Retroviral transduction with MSCV2.2-MLL-AF9-IRES-GFP
was performed as described [26,28]. Briefly, bone marrow cells of
wild type and Par1-knockout recipients were isolated, AKC-lysed
and transduced as described previously [26]. 90.000 (MLL-AF9)
GFP-positive cells were transplanted by tail-vein injection into
C57Bl/6N wild type recipients, which were lethally irradiated with
8 Gy.
For secondary transplantation, bone marrow cells of leukemic
mice were isolated of three independent donors of each genotype
and 16106 MLL-AF9/GFP-positive cells of each donor were
intravenously injected into irradiated secondary C57Bl/6N wild
type mice.
Tertiary C57Bl/6N recipient mice were irradiated with 8 Gy
and transplanted with 100 or 1000 ckit+ MLL-AF9 blasts isolated
from six secondary recipients (three of each genotype). Frequencies
of leukemia initiating cells (LICs) from tertiary transplanted mice
were calculated using the L-Calc program (StemCell technologies,
Inc.).
For the rescue experiment, leukemic spleen cells were retrovi-
rally transduced as described above with an empty vector
MSCV2.2-IRES-mCherry or with MSCV2.2-PAR1-IRES-
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mCherry, which contained blunt-ended human PAR1 cDNA
cloned into a blunted XhoI site 59 of the IRES. Cells were stained
with a c-kit-APC antibody and sorted by FACS for c-kit, GFP and
mCherry expression. 1,000 triple positive cells were transplanted
into six irradiated recipient mice per group.
All transplanted mice were dosed with Cotrim (100 mg/l)
(Ratiopharm, Ulm, Germany) until two weeks after transplanta-
tion. The results of the survival experiments were analysed with
the log-rank non-parametric and represented as Kaplan-Meier
survival curves.
Cloning efficiency assays of murine leukemic blasts
To determine the cloning efficiency of bone marrow cells,
different concentrations of bone marrow cells of untreated mice or
leukemic blasts of mice that were transplanted with leukemic blasts
from the primary transplantation experiment were FACS-sorted.
1, 10, 30, 100 and 300 c-kit-and, GFP-positive cells of Par1+/+;
MLL-AF9 or Par12/2;MLL-AF9 bone marrow cells were then
seeded in 200 ml methylcellulose in 14 wells of a 48-well plate. 7
days later wells with one or more colonies were classified as
positive. The stem cell frequency was determined by Poisson
statistical analysis (L-calc software, StemCell Technologies).
Results
PAR1 expression profile in hematopoietic cells
Recent studies hint at a role for PAR1 in the hematopoietic
system [14]. To address a potential role for PAR1 in hematopoi-
esis, we used published microarray data [22] to analyse PAR1
expression in multiple human hematopoietic cell types. As
expected, PAR1 expression was high in cells of the erythroid/
megakaryocytic lineage (Fig. 1A). Moreover, PAR1 was promi-
nently expressed in hematopoietic stem cells (HSC), while its
expression decreased upon differentiation in myeloid and
lymphoid progenitor cells (Fig. 1A). Such a distinct expression
pattern could not be detected for the other three proteinase-
activated receptors PAR2, PAR3 or PAR4 (Fig. S1A-C).
To analyse the function of Par1 especially in the adult mice,
which was not addressed yet [12], we determined Par1 expression
in subpopulations of mouse bone marrow. We sorted primary cells
by flow cytometry (Fig. 1B) and isolated RNA. In line with the
microarray results of human hematopoietic cells (Fig. 1A), real-
time RT-PCR demonstrated that Par1 mRNA was most abundant
in the stem cell compartment (Fig. 1B, upper right panel). Par1
expression was also present in multipotent progenitor (MPPs,
Fig. 1B, upper right panel) and common lymphoid progenitor
(CLP). PAR1 was also expressed in CD3-positive T-cells in
peripheral blood (Fig. 1B, lower right panel). Expression of PAR1
was notably absent in the more differentiated B220+, Ter119+ or
CD11b+ bone marrow cells (Fig. 1B, lower right panel).
Absence of Par1 does not interfere with normal
hematopoiesis
Since Par1 was mostly expressed in stem cell fractions of
primary bone marrow mouse cells, a function of Par1 in
undifferentiated hematopoietic cells could be possible. We
analyzed adult hematopoiesis in a previously generated Par1-
knockout mouse model [12]. As published, we also faced a more
than 50% underrepresentation of Par12/2 adult mice (see
Materials and Methods).
We determined the function of Par1 in the regulation of stem
cell growth by comparing the phenotype of wild type and Par1-
deficient mice. We determined a spectrum of blood parameters
such as white blood cells count, composition of the blood
according to surface markers and hemoglobin (Table 1) and
found out that the blood composition was not altered in Par1-
deficient mice in any parameter tested. Also, the number of
hematopoietic stem and progenitor cells was similar (Fig. 2A). To
determine the potential of Par12/2 bone marrow cells to form
colonies in methylcellulose, we performed colony assays using total
bone marrow and c-kit+ bone marrow cells. The colony formation
potential was not altered by Par1 deficiency (Fig. 2B). Also,
differentiation of these colonies was unchanged between both
genotypes (data not shown). Moreover, two serial replatings of the
colonies formed from Par1+/+ and Par12/2 cells did not reveal
differences (data not shown).
Although the phenotypic number of HSCs was unchanged in
Par1-deficient bone marrow, these cells could potentially behave
differently in vivo and reveal a function of Par1 in hematopoietic
stem/progenitor cell differentiation or proliferation after trans-
plantation. Therefore, we transplanted wild type and Par1-
knockout bone marrow cells in different concentrations as limiting
dilution assay into wild type recipients (Fig. 2C). No significant
differences were observed at 4 or 16 weeks that would indicate
altered short- and long-term hematopoietic stem cell functions,
respectively. Par1-deficient cells tended to perform better than wild
type cells upon transplantation since the frequency of Par1-
deficient cells that were detectable in the blood was higher than
the frequency of wild type cells without reaching statistical
significance (Fig. 2C, right-hand side).
Interestingly, bone marrow cells that retrovirally overexpressed
PAR1 as depicted schematically in Fig. 2D were significantly less
abundant four weeks after transplantation in wild type recipients
than control cells transduced with the empty vector (Fig. 2F).
These cells were not impaired in their colony formation ability
(Fig. 2E). Contribution to blood cell formation was not changed
(data not shown). Remarkably, Par1 did not induce a proliferative
advantage in non-transformed cells.
In conclusion, neither loss nor overexpression of Par1 interferes
with normal hematopoiesis.
PAR1 expression is significantly decreased in blasts of
AML patients
Thrombin receptors have long been implicated in the develop-
ment of malignant diseases [16]. Especially PAR1 expression was
correlated to cell migration and metastasis in different tumor
entities [15,17,18,19,20,21] but its expression and function in
leukemia was unknown.
Although the activity of receptors is tightly regulated on protein
levels, PAR1 recovery might also rely on new protein synthesis and
therefore on the abundance of its mRNA in some cell types
including cells from the hematopoietic system [30]. Hence, we
analyzed the expression of PAR1 in a large set of leukemia patient
samples using Gene expression microarrays for mRNA analyses
(Fig. 3) and real-time RT-PCR (Fig. 3) and a tissue microarray for
protein expression (Fig. 4).
The mRNA analysis of five CD34+ cells of healthy donors and
64 AML patients revealed that PAR1 expression was markedly
lower in AML blasts than in CD34+ progenitor cells (Fig. 3A),
whereas the expression of the other three family members did not
differ (Fig. 3B-D). Detailed analysis of PAR1 expression demon-
strated its significant downregulation in all FAB subtypes of AML
(Fig. S2A). AML patients with high PAR1 expression (level .9 log
arbitrary units in this microarray analysis) did not reveal changes
in hemoglobin, LDH, number of platelets, white blood cells or
blasts in the blood or bone marrow at the time of diagnosis
compared to patients with lower PAR1 expression (level ,9 log
arbitrary units in this microarray; data not shown). PAR1
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Figure 1. PAR1 is expressed in hematopoietic cells. 1A. PAR1 was analyzed in mRNA microarray expression data from FACS sorted bone
marrow cells [22,23]. Highest expression was found in hematopoietic stem cells (HSC) and cells of the erythroid/megakaryocyte and of the T-cell
lineage. Shown here are log arbitrary units. 1B. Left-hand side: To sort for the different murine bone marrow subpopulation, total bone marrow was
stained with lineage-markers, sca1 and c-kit. Lineage-negative, sca1+, c-kit+ (LSK) cells were further divided into long-term (LT)-HSCs as Flt32CD342
population, short-term (ST)-HSCs as Flt32CD34+ cells and multipotent progenitors (MPPs) as Flt3+CD34+ cells (upper panel). Common lymphoid
progenitors (CLPs) were defined as lineage-negative, IL7R+c-kit+ cells. Upper and lower right panel: Par1 mRNA expression was determined by real-
time quantitative RT-PCR using cDNA from the FACS-sorted murine bone marrow subpopulations and Par1 expression was normalized to GAPDH
expression. Par1 was expressed in all hematopoietic stem/progenitor subpopulations and CD3+ T-cells whereas monocytes/macrophages/
granulocytes (CD11b+) or erythrocytic (Ter119+) or B-cells (B220+) expressed low or no Par1.
doi:10.1371/journal.pone.0094993.g001
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Figure 2. PAR1 function in proliferation and differentiation. 2A. Stem cell FACS analysis revealed similar numbers of stem and progenitor
subpopulations (n = 3 mouse pairs for each FACS). Shown here are the percentage of lin2sca1+c-kit+ (LSK) cells from the lineage-negative parental
population and the percentage of longterm (LT)-HSCs, shortterm (ST)-HSCs and multipotent progenitors (MPP) from the parental LSK population. 2B.
Colony assays of cells from Par1+/+ and Par12/2 total bone marrow (left-hand side) and c-kit+ bone marrow cells (right-hand side; n = 3 mouse pairs
PAR1 Regulates Leukemic Stem Cells
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expression also did not influence overall survival or relapse-free
survival (data not shown). Of note, the expression of the main
upstream regulator of PAR1 function, the ligand Thrombin, was
unchanged (Fig. 3E).
We confirmed PAR1 expression by quantitative real-time RT-
PCR in CD34-positive cells from healthy patients and samples
from AML patients (Fig. 3F) in an independent cohort of patients.
Compared to CD34+ cells, PAR1 expression was again signif-
icantly decreased in all AML subtypes (Fig. 3F).
To analyze the protein expression of PAR1 in control and AML
patient samples, we used immunohistochemical detection of PAR1
on a tissue array that included CD34-positive cells as well as
sections of bone marrow punches. Remarkably, tissue array
analysis of PAR1 expression revealed that PAR1 was more
prominently expressed in CD34+ cells from healthy volunteers
compared to AML blasts (Fig. 4A and B). Only 30 out of 119 AML
patient samples showed PAR1-expression (25%), whereas 5 out of
7 samples of CD34+ cells were positive for PAR1-expression (71%;
Fig. 4B) (p = 0.008, Chi-square test [31]). The finding of PAR1
protein expressing AML samples (Fig. 3F) suggest that PAR1
protein might be present although mRNA levels were very low in
most AML patients. Immunohistochemistry staining might also
pick up other PAR proteins, which might be expressed in certain
AML samples (Fig. 3C and D). Nonetheless, PAR1 mRNA and
protein data are highly concordant with loss of expression in most
of the specimens. Also, these results were in accordance with the
observed differences in the Par1 expression in sorted mouse bone
marrow cells, in which Par1 was highly expressed in the stem cell
compartment and in progenitor cells (Fig. 1B). In line with the
results obtained in the microarray analysis, PAR1 expression did
not correlate with hemoglobin, number of platelets, white blood
cells or blasts in the blood or the bone marrow at the time of
diagnosis (data not shown). Also, different PAR1 levels were not
associated with the overall survival time or the relapse-free survival
of the patients (data not shown). Interestingly, in this analysis
PAR1 expression was especially low in AML M2, M4 and M5
(Fig. 4C).
PAR1-deficiency enhances leukemic stem cell potential
The observation that PAR1 expression differed significantly in
human acute myeloid leukemia and especially in AML M4 and
M5 (Fig. 4C) led us to analyze Par1 functions in murine
leukemogenesis. To model AML in vivo, wild type or Par1-
knockout (2/2) bone marrow cells were retrovirally transduced
with the leukemogenic MLL-AF9, which occurs in human AML
M5 [32] and reliably induces an AML in mice [33,34,35].
Transplantation of 90.000 positive cells as assessed by GFP
expression (Fig. 5A) of bone marrow cells retrovirally transduced
with the oncogene MLL-AF9 induced myeloid leukemia both in
wild type and Par12/2 bone marrow cells with comparable
latency, penetrance, and morphology (Fig. 5B and data not
shown). Acute myeloid leukemia in mouse models is defined by
transplantability into secondary recipients [36]. Transplantation
into secondary recipients assesses leukemic stem cell function.
Interestingly, Par1-deficiency significantly accelerated the leukemic
disease in secondary recipients (Fig. 5C; p,0.001). Of note, this
finding was cell intrinsic, since all recipients were of Par1 wild type
genotype. Both genotypes generated an acute myeloid leukemia
after secondary transplantation (Fig. 5D).
for each experiments). No significant changes in the ability of forming colonies were observed in any cell population. 2C. Left-hand side: Bone
marrow cells from CD45.2+ Par12/2 or Par1+/+ mice were mixed with Par1+/+ bone marrow from congenic CD45.1+ as depicted in the schematic
overview. Right-hand side: At 16 weeks after transplantation, the number of negative responders, which were transplanted with Par12/2 bone
marrow, did not differ from wild type transplanted mice. Therefore, the stem cell frequency was comparable in the bone marrow of both genotypes.
2D. Schematic outline of the transplantation experiment using PAR1-overexpressing lineage-negative bone marrow cells compared to control cells
transduced with the empty vector. 2E. Colony formation of bone marrow cells transduced with empty vector (‘‘control’’) or with a PAR1 expressing
retroviral vector (‘‘pMY-PAR1’’) was not significantly different between the two groups. 2F. Transplantation of cells as depicted in Figure 2D lead to a
significantly lower ratio of PAR1-overexpressing cells after four weeks.
doi:10.1371/journal.pone.0094993.g002
Table 1. Blood parameters of wild type and Par12/2 mice.
3 months 6 months
Parameters Par1+/+ Par12/2 Par1+/+ Par12/2
WBC [103/ml] 9.661.7 9.262.9 6.961.9 7.263.1
RBC [106/ml] 8.860.5 9.060.8 8.560.5 8.461.6
HGB [g/dl] 14.060.9 14.261.1 13.360.6 13.162.4
HCT [%] 45.862.8 46.764.2 43.962.4 42.768.4
MCV [fL] 52.260.6 51.960.9 51.760.7 50.960.7
MCH [pg] 15.960.2 15.860.5 15.760.4 15.760.4
MCHC [g/dl] 30.560.4 30.460.9 30.460.5 30.861.0
PLT [103/ml] 914.46204.4 780.66176.0 736.66174.3 765.36359.5
FACS
B220+ [%] 54.163.0 55.665.3 50.366.1 42.5611.8
CD3+ [%] 23.067.9 26.666.7 25.563.8 26.366.1
CD11b+ [%] 18.866.0 16.963.1 14.865.0 17.6612.8
The data show mean values of 11 wild type and 11 Par12/2 blood analyses at the age of three months and mean values of 10 wild type and 10 Par12/2 blood
preparations at the age of 6 months. WBC, white blood cell count; RBC, red blood cell count; HGB, haemoglobin; HCT, hematocrit; MCV, mean corpuscular volume; MCH,
mean corpuscular haemoglobin; MCHC; mean corpuscular haemoglobin concentration; PLT, platelets. B220+, B-cells; CD3+, T-cells; CD11b+, myeloid cells.
doi:10.1371/journal.pone.0094993.t001
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Figure 3. PAR1 mRNA expression in primary patient samples. PAR1 expression (3A) was significantly down-regulated in bone marrow cells
from human Acute Myeloid Leukemia (AML; n = 67) patients compared to sorted CD34+ cells (n = 5) in microarray analysis, while the expression of
PAR2 only showed a non-significant trend (3B), and the expression of PAR3 (3C), PAR4 (3D) and Thrombin (3E) was unchanged. Shown here are log
arbitrary units. 3E. PAR1 expression was significantly downregulated in bone marrow cells from human Acute Myeloid Leukemia (AML) patients
compared to CD34-positive bone marrow cells. PAR1 expression was determined by qRT-PCR and normalized to GAPDH expression level.
doi:10.1371/journal.pone.0094993.g003
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Figure 4. PAR1 expression in primary patient samples. 4A. Micrographs of Tissue Array analysis from NBM and AML patients stained with anti-
PAR1 antibody and Fast-Red secondary antibody contrasted with hematoxylin and eosin. Overview (upper panel) and magnification of one example
of CD34+ and AML samples that were defined PAR1-negative (lower left) and PAR1-positive (lower right). 4B. Quantitative Tissue Array analysis of
PAR1 expression using categories of staining intensity as positive or negative. Significantly more AML patient samples were negative for PAR1
expression than CD34+ healthy patient samples (p = 0.003, Chi-square test). 4C. PAR1 protein was significantly less abundant in bone marrow cells
from human Acute Myeloid Leukemia (AML) patients compared to CD34-positive bone marrow cells in Tissue Array samples. *p,0.05, Chi-square
test.
doi:10.1371/journal.pone.0094993.g004
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Figure 5. Absence of Par1 accelerates MLL-AF9 driven murine leukemogenesis. 5A. Schematic overview about the performed transduction
and transplantation experiments. Bone marrow isolated from Par1+/+ or Par12/2 mice was retrovirally transduced with MLL-AF9/GFP. Equal numbers
of positive cells were transplanted into lethally irradiated recipients, which were then subjected to different analyses and subsequent serial
transplantations. 5B. Survival curves of recipient mice which were transplanted with bone marrow cells of Par1+/+ or Par12/2 mice that were
retrovirally transduced with MLL-AF9 (n = 8 of each genotype). Cells of both genotypes led to a fatal leukemic disease with comparable latency. 5C.
Survival curves of secondary recipient mice which were transplanted with bone marrow cells of leukemic mice derived from the primary
transplantation shown in Fig. 5B. The secondary recipients of Par12/2;MLL-AF9 cells (n = 14) died after a significantly shorter latency than mice
transplanted with Par1+/+;MLL-AF9 primary blasts (n = 15; p,0.001). 5D. The phenotypic analysis of blasts of the secondary leukemic mice did not
reveal differences in CD11b expression between Par1+/+;MLL-AF9 and Par12/2;MLL-AF9 cells. 5E. Par12/2;MLL-AF9 transplanted mice (n = 8) exhibited
a strong tendency towards higher percentages ofc-kit expressing cells in spleens (p = 0.055, t-test) and bone marrow (p= 0.22, t-test)compared to
Par1+/+;MLL-AF9 transplanted mice (n = 4).
doi:10.1371/journal.pone.0094993.g005
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In murine MLL-AF9 leukemias, the c-kit positive fraction
contains the leukemic stem cells [33]. We determined the fraction
of c-kit+ blasts within the GFP+ cells to determine whether the
phenotypic stem cell fraction was altered. In spleen as well as in
bone marrow, the fraction of c-kit+ stem cells was increased in the
Par12/2 blasts (Fig. 5E). In spleen, the mean percentage of c-kit
positive cells was 24.3% in wild type leukemias but 48.1% in
leukemias with Par1-deficiency. Also, half of the leukemias with
wild type Par1 showed less than 20% c-kit positive cells whereas all
Par1-deficient leukemias harbored more than 20% of c-kit positive
cells (Fig. 5E).
Par1 restricts the leukemic stem cell pool size and
function
We hypothesized that loss of Par1 led to an expansion of the
leukemic stem cell pool with enhanced stem cell activity. To test this
hypothesis, we performed cloning efficiency experiments of c-
kit+GFP+ bone marrow cells (as depicted in Fig. 5A) from leukemic
mice after secondary transplantation to determine the fraction of
MLL-AF9 expressing cells that could give rise to clonal growth.
MLL-AF9-positive cells from secondary transplanted mice were
sorted according to their c-kit- and GFP-positivity and seeded in cell
numbers from 1 to 300 cells per well in methylcellulose in 48-well
plates and the clone forming efficiency was determined according to
Poisson-statistics. Par12/2;MLL-AF9 cells exhibited a cloning
efficiency of 1/1.7, while the cloning efficiency of Par1+/+;MLL-
AF9 cells (1/3.4) was two times lower (Fig. 6A; p= 0.047).
Interestingly, non-transduced c-kit+ Par12/2 bone marrow cells,
which were seeded in the same way to determine their cloning
efficiency capacity, did not form more clones than wild type bone
marrow cells (data not shown).
To determine the frequency of leukemia initiating cells (LICs) in
vivo, we transplanted 100 and 1000 c-kit+ cells of secondary
transplanted leukemicmice serially into irradiated tertiary recipients
as depicted in Fig. 6B. Recipients that received Par1+/+ blasts
survived significantly longer than those that received Par12/2 cells
(Fig. 6C, left-hand side). From this transplantation, we determined
the frequency of LICs in both genotypes according to the positive
responder mice that died due to leukemia by Poisson-statistics
(Fig. 6C, right-hand side). The frequency of LICs was about four
times higher in absence of Par1 (1/56) than in presence of Par1 (1/
256; p= 0.0166), which most likely contributed to the shortened
latency and higher penetrance in this transplantation.
Re-expression of Par1 restricts leukemic stem cell
function
Since the absence of Par1 enhanced leukemogenesis, we
hypothesized that re-introduction of Par1 expression in Par1-
deficient leukemic blasts could decelerate the disease. Hence, we
used MLL-AF9 positive splenic wild type and Par12/2 blasts from
primary transplanted mice (Fig. 5B) and transduced them with a
retroviral construct that expressed human PAR1 and the red
fluorescent protein mCherry or as a control the empty vector only
expressing mCherry. Cells were sorted by flow cytometry for their
expression of MLL-AF9 (GFP), mCherry and c-kit as a marker for
MLL-AF9 LICs. Each mouse received 1,000 triple-positive cells
(Fig. 6D, left-hand side; n= 6 for each group). As expected from
the results obtained from transplantation of 1,000 c-kit+ MLL-AF9
splenic cells before (Fig. 6C), blasts of both genotypes transduced
with the control vector led to a rapid disease with comparable
latency (Fig. S3). In contrast, overexpression of PAR1 in Par12/2
blasts significantly extended the survival time of recipient mice
compared to mice transplanted with PAR1-overexpressing wild
type MLL-AF9 blasts (Fig. 6D, right-hand side; p = 0.013).
Moreover, overexpressing of PAR1 in cells with wild type levels
of endogenous Par1 do not exhibit a significantly altered survival
time compared to the control groups (Fig. S3).
In conclusion, Par1 acts as controller of leukemic stem cells in
MLL-AF9 triggered murine leukemia and leukemic mice lacking
Par1-expression in their blasts benefit from recovery of Par1
function.
Discussion
Our study reveals that PAR1 is especially expressed in healthy
hematopoietic stem cells, whereas PAR1 expression is markedly
lost in acute myeloid leukemia. The loss of Par1 leads to enhanced
leukemic stem cell function in vivo.
Members of the hematopoietic serine protease superfamily that
activate PARs, such as cathepsin G, neutrophile elastase and
proteinase 3, may play an important role in myeloid biology [37].
Patients, who suffer from hematological disorder or congenital
neutropenia frequently exhibit mutations in genes for neutrophil
serine-proteases or show alterations in its expression, localisation
or activity [38]. Nonetheless, PAR1 is not required in normal
hematopoiesis and HSC function. The dispensability of Par1 in
these processes might rely on redundant action of other
proteinase-activated receptors, as it was already assumed for
Par2 in thrombin-induced responses in Par12/2 platelets [12].
Moreover, persistent thrombin signalling in Par3-deficient platelets
led to the identification of Par4 [39]. To determine the role of
other PAR family members in hematopoiesis will require further
experiments like the generation of Par1/Par2-double deficient
mice, which might be difficult using the straight knockout mice
due to the limited survival of both single-mutant mouse models
[12,40]. For this kind of experiments, the generation of conditional
knockout mouse lines might be necessary.
Up to now, PAR1 was assigned to oncogenic function in many
tumor entities [2,16,18,19,41]. We were intrigued by the
widespread loss of PAR1 in AML blasts by integrating the
expression levels of PAR1 in three different leukemia patient
cohorts on mRNA and protein levels. We therefore tested the role
of Par1-deficiency in mouse leukemia. The oncogenic translocation
product MLL-AF9 is frequently found in human leukemias
[42,43]. We took advantage of the fact that PAR1 protein
expression was downregulated in human AML patient samples of
FAB subtypes M4 and M5 in our tissue arrays (Fig. 5C) and that
these AML subtypes can be modelled by the retroviral introduc-
tion of MLL-AF9 in hematopoietic progenitors [34]. The AML-
like phenotype is readily induced by MLL-AF9 in mice, either as a
stable knockin [44] or by transient retroviral transduction and
transplantation [34]. The widely-accepted concept of leukemic
stem cells [45] can be recapitulated very consistently in this
leukemia model, since predominantly the c-kit+ fraction of MLL-
AF9 positive leukemic blasts is transplantable and capable of self-
renewal comparable to normal HSCs [34,35].
We discovered that Par1 expression restricted the pool of
functional leukemic stem cells, rather than promoting it as an
oncogene. Many receptors have been assigned as oncogenes, also
in leukemogenesis. Prominent examples are the receptor-tyrosine
kinases like FLT3 [46] and c-KIT [47]. But usually, these
receptors are overexpressed or constitutively active due to
mutations, which lead to overactivation of downstream targets,
or to misactivation of other targets. In the case of PAR1, the
mechanism of action in leukemogenesis might be different.
Absence of Par1 enhances leukemia development, which might
indicate vice versa that wild type expression of Par is able to suppress
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Figure 6. Leukemia initiating cells are regulated by Par1. 6A. For a cloning efficiency assay, Par1+/+;MLL-AF9 or Par12/2;MLL-AF9 bone
marrow cells from leukemia-transplanted mice were FACS-sorted and 1 to 300 c-kit+GFP+ cells were seeded in semi-solid medium in a 48-well plate.
Par1+/+ cells had a clone forming frequency of 1/3.4, while the frequency was much higher in Par12/2 cells (1/1.7; p = 0.047). Shown here are the
mean results of three independent experiments. 6B. Schematic overview about the serial transplantations performed with MLL-AF9 leukemic blasts.
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leukemogenesis to a certain extent. Recently, it was shown that
Par1 signal transduction might occur via the RhoA/ROCK1
pathway [14,48], which is also implicated to influence hemato-
poietic stem cells [49]. It will be interesting to investigate to which
extent an alteration in this or another signal pathway in involved
in the phenotype of Par1-deficient MLL-AF9 leukemic mice.
Although it was somewhat surprising that Par1 acted as a
suppressor of stem cell function in leukemia, whereas it is
implicated as an oncogene in other cancer entities, several other
prominent factors also display such divergent functions. One
example is the polycomb complex protein EZH2 that acts as an
oncogene i.e. in prostate and breast cancer [50,51], while it
suppresses T-cell leukemia development in mice [52]. In addition,
Notch1 signalling is intensively studied and discussed as oncogene
in different tumors and as tumor suppressor in leukemias
[53,54,55]. Therefore, it is quite possible that Par1 acts with
divergent outcome in different cancers. In addition, also its close
relative Par2 was already identified as tumor suppressor in a model
for skin carcinogenesis [56], although Par2 was also mostly
accepted as oncogene [57,58], which illustrates the diverse
functions that can be expected in this receptor family.
Finally, the fact that mice transplanted with Par1-deficient
MLL-AF9 blasts benefit from the re-activation of Par1-expression
might suggest that this could also help as a therapy for patients
initially expressing very low or no PAR1. Rendering leukemic
stem cells responsive to leukemia therapy is still a big task with the
goal to be able to ultimately eradicate the disease (reviewed in
[59]). Further studies on the role of Par1 in different leukemias
might help to understand leukemic stem cell function and to
develop molecular therapies to target these cells.
Supporting Information
Figure S1 PAR2, PAR3 and PAR4 expression in hema-
topoietic cells. Expression of PAR2 (S1A), PAR3 (S1B) and
PAR4 (S1C) was analyzed in published microarray data from
FACS sorted bone marrow cells (22, 23). None of them was
prominently expressed in hematopoietic stem cells (HSC). Shown
here are log arbitrary units.
(EPS)
Figure S2 PAR1 expression determined in microarray
analysis according to FAB subtypes. PAR1 is significantly
less expressed in all FAB subtypes tested by microarray analysis.
(EPS)
Figure S3 Empty vector controls to PAR1-overexpres-
sion transplantation. Survival curve of mice that were
transplanted with MLL-AF9-induced Par1-wt and -ko leukemic
spleen blasts that were additionally transduced with MSCV-IRES-
mCherry empty vector. Mice that were transplanted with these
cells exhibited leukemia initiation with comparable latency.
(EPS)
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